Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial
Marco Ripa(Vita-Salute San Raffaele University), Giuseppe Tambussi(San Raffaele University of Rome), Adriano Lazzarin(Vita-Salute San Raffaele University), Gabriella Scarlatti(Istituti di Ricovero e Cura a Carattere Scientifico), Davide De Battista(Vita-Salute San Raffaele University), Mauro Malnati(Vita-Salute San Raffaele University), Laura Galli(Vita-Salute San Raffaele University), Manuela Pogliaghi(Hôpital Fernand-Widal), Stefania Chiappetta(Vita-Salute San Raffaele University), Silvia Nozza(IRCCS Ospedale San Raffaele), Andrea Cossarizza(University of Modena and Reggio Emilia), Sara De Biasi(University of Modena and Reggio Emilia), Mariangela Cavarelli(Inserm), Simone Pensieroso(Vita-Salute San Raffaele University)
Cited by 14
Related Papers
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
|European Journal of Immunology|2019|1k
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|The Lancet Rheumatology|2020|998
Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia
|Nature Communications|2020|846
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653